EWPI Emerging World Pharma Inc (CE)

Emerging World Pharma Inc. (PINKSHEETS: EWPI), an investor in generic based pharmaceutical companies manufacturing within developing nations, has provided an initial investment into a private generic pharmaceutical company located in West Africa. The investment would entitle Emerging World Pharma a percentage of profits obtained from an exclusive marketing and distribution agreement of generic pharmaceuticals. In addition the company has negotiated an option that would considerably increase the percentage of returns on profit with ongoing investments.

The drugs manufactured will be marketed and sold for private and public sale and use throughout West Africa.

Comprising almost a third of the whole continent, West Africa is a region with a population of approximately 250 million. Imports of finished products account for over 60% of the African pharmaceutical industry. According to IMS forecast, Nigeria's Pharma business is worth $2.5 billion serving 150 million Nigerians. The pharmaceutical market in West Africa has been growing 5% - 7% annually with over 200 active manufacturers of pharmaceuticals in West Africa, there are great opportunities for investment and development.

"This preliminary agreement sets the ground work for what we expect to be a long term business relationship in this generic pharmaceutical sector. The potential for continued growth in this market of West Africa is staggering," stated Emerging World Pharma president, Brandon Keks.

The company will provide additional details of the agreement in subsequent press releases and on the company's website. www.emergingpharma.com

About Emerging World Pharma Inc.

Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.

The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups: church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact: Joel Everret Emerging World Pharma Inc. Investor Relations Division 703-646-2633 Email: info@emergingpharma.com